We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Better Biosensors Made with Electron Density Waves

By LabMedica International staff writers
Posted on 18 Nov 2010
An emerging field called optofluidic plasmonics has the potential for a new way to detect and analyze biologic molecules for drug discovery, medical diagnostics, and the detection of biochemical weapons. More...


Investigators from the University of California, San Diego (UCSD; USA) led by Dr. Yeshaiahu Fainman have succeeded in merging a microfluidics system with plasmonics--also called "light on a wire”--onto a single platform. Plasmonics is based on electron waves on a metal surface excited by incoming light waves.

According to Dr. Fainman, tapping the potential of plasmonics for biomolecule detection systems has been a challenge, because localized optical field scales are usually much larger than the molecules being studied. In order to make a useful optical biosensor, he stated, "We need to increase the interaction cross-section by finding ways to localize optical interrogation fields ideally to the scales comparable to those of biomolecules.”

Since that is not currently possible, he and his team used an approach of integrating microfluidics and plasmonics on single chips, allowing fluid to transport the molecules into the cross-section of the optical field. Dr. Fainman expects the system to be especially beneficial in examining large arrays of protein-protein interactions for identifying potential drugs that bind to specific target molecules, which may lead to earlier cancer diagnoses and faster discovery of new drugs. Unlike most traditional techniques, optical detection does not require labeling of molecules with fluorescent or radioactive entities--labels frequently suppress interaction by covering up or blocking binding surfaces.

The new platform also carries the advantage of being high throughput and multiplexed, offering researchers an opportunity to examine thousands of arrayed compounds simultaneously, which Dr. Fainman concluded, "Biologists and physicians get very excited about.”

The study's findings were presentation, presented October 26, 2010, at the Frontiers in Optics (FiO) 2010/Laser Science XXVI--the 94th annual meeting of the Optical Society (OSA), which was held together with the annual meeting of the American Physical Society (APS) Division of Laser Science in Rochester, NY, USA, from October 24-28.

Related Links:
University of California, San Diego


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.